Increlex gets Priority Review

Tercica (TRCA) said FDA accepted for filing and granted Priority Review to an NDA for Increlex mecasermin to treat growth failure in children with a severe form of primary insulin-like growth factor-1 deficiency (IGFD). The NDA has an Aug. 31 PDUFA date. TRCA licensed exclusive rights to the recombinant human insulin-like growth factor-1 ( rhIGF-1) from Genentech (DNA). ...